ArticleJournal for immunotherapy of cancer2021
Type 17 immunity promotes the exhaustion of CD8
Article in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 46 citations in OpenAlex.
- DYRK kinases phosphorylate IL-17RA at S801.Serican journal of medicine · 2026Article
- Deceptive initial presentation of systemic DLBCL with CNS progression following Oligometabolic PET/CT: case report.Frontiers in oncology · 2026Article
- Categorizing immunotherapy resistance mechanisms in non-small cell lung cancer: how can we perform better?Journal for immunotherapy of cancer · 2025Review
- T cell exhaustion‑related gene CD79B predicts prognosis, inhibits malignant progression and promotes tumor‑associated macrophage M1‑like polarization in lung adenocarcinoma.Oncology reports · 2025Article
- TIM3Cancer cell · 2025Article
- PD-1 blockade treatment in melanoma: Mechanism of response and tumor-intrinsic resistance.Cancer science · 2025Review
- Analysis of tumor-infiltrating exhausted T cells highlights IL-6 and PD1 blockade as a combined immunotherapy strategy for non-small cell lung cancer.Frontiers in immunology · 2025Article
- Myeloid cells meet CD8Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024Article
- Cytotoxic T Cells Drive Outcome in Inflammatory Dilated Cardiomyopathy.Circulation research · 2024Article
- Prolonged Survival of Neutrophils Induced by Tumor-Derived G-CSF/GM-CSF Promotes Immunosuppression and Progression in Laryngeal Squamous Cell Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Immune Biomarkers at Birth Predict Lower Respiratory Tract Infection Risk in a Large Birth Cohort.Pathogens (Basel, Switzerland) · 2024Article
- Recent developments in immunotherapy for gastrointestinal tract cancers.Journal of hematology & oncology · 2024Review
- TimiGP-Response: the pan-cancer immune landscape associated with response to immunotherapy.bioRxiv : the preprint server for biology · 2024Article
- Long-term antigen-specific immune response by an oncolytic adenovirus encoding SP-SA-E7-4-1BBL in HPV-16 cancer model.Molecular biology reports · 2024Article
- IL-17 and IL-21: Their Immunobiology and Therapeutic Potentials.Immune network · 2024Review
- Gut epithelial Interleukin-17 receptor A signaling can modulate distant tumors growth through microbial regulation.Cancer cell · 2024Article
- The role of interleukin-17 in inflammation-related cancers.Frontiers in immunology · 2024Review
- Modulation of CD8International journal of molecular sciences · 2023Review
- CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential.Experimental & molecular medicine · 2023Review
- Abnormal generation of IL-17A represses tumor infiltration of stem-like exhausted CD8BMC medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple types of immune cells producing IL-17 are found in the tumor microenvironment. However, their roles in tumor progression and exhaustion of CD8
methodsTo determine the role of type 17 immunity in tumor, we investigated the growth of B16F10 melanoma and the exhaustion of CD8
resultsDepletion of CD4
conclusionIL-17-producing cells promote terminal exhaustion of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.